EKSO - Ekso Bionics Holdings Inc Stock Price, Fair Value and News

1.36USD-0.09 (-6.21%)Delayed

Market Summary

USD1.36-0.09

Delayed

-6.21%

EKSO Stock Price

View Fullscreen

EKSO RSI Chart

EKSO Valuation

Market Cap

24.7M

Price/Earnings (Trailing)

-1.74

Price/Sales (Trailing)

1.38

Price/Free Cashflow

-2.16

EKSO Price/Sales (Trailing)

EKSO Profitability

Return on Equity

-101.33%

Return on Assets

-49.17%

Free Cashflow Yield

-46.24%

EKSO Fundamentals

EKSO Revenue

Revenue (TTM)

17.9M

Rev. Growth (Yr)

-8.88%

Rev. Growth (Qtr)

-22.51%

EKSO Earnings

Earnings (TTM)

-14.2M

Earnings Growth (Yr)

21.87%

Earnings Growth (Qtr)

-6.69%

Breaking Down EKSO Revenue

Last 7 days

0.7%

Last 30 days

6.3%

Last 90 days

-33.3%

Trailing 12 Months

-15.5%

How does EKSO drawdown profile look like?

EKSO Financial Health

Current Ratio

2.81

EKSO Investor Care

Shares Dilution (1Y)

34.60%

Diluted EPS (TTM)

-1.1

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	17.9M	0	0	0
2023	14.4M	15.8M	17.1M	18.3M
2022	11.9M	13.0M	13.3M	12.8M
2021	8.2M	8.1M	8.3M	11.2M
2020	11.8M	10.8M	10.3M	7.8M
2019	12.4M	12.7M	13.5M	13.9M
2018	8.4M	9.5M	10.5M	11.3M
2017	7.2M	7.5M	7.5M	7.4M
2016	15.5M	14.9M	13.6M	14.2M
2015	6.0M	6.9M	8.2M	8.7M
2014	3.7M	3.9M	4.6M	5.3M
2013	3.4M	4.4M	5.2M	3.3M
2012	0	0	0	2.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Ekso Bionics Holdings Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 22, 2024	wong jerome	acquired	-	-	7,474	chief financial officer
Mar 22, 2024	jones jason c	acquired	-	-	7,474	chief operating officer
Nov 02, 2023	lathan corinna	bought	5,004	1.2412	4,032	-
Aug 23, 2023	lathan corinna	bought	5,221	0.9494	5,500	-
Aug 17, 2023	davis scott g.	sold	-37,281	0.9956	-37,446	president & coo
Aug 17, 2023	wong jerome	sold	-12,727	0.9956	-12,784	chief financial officer
Aug 10, 2023	lathan corinna	bought	5,251	1.25	4,201	-
Jun 12, 2023	wong jerome	acquired	-	-	170,068	chief financial officer
Jun 12, 2023	jones jason c	acquired	-	-	10,800	chief operating officer
Jun 12, 2023	wong jerome	acquired	-	-	8,200	chief financial officer

Which funds bought or sold EKSO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	unchanged	-	-26,425	31,525	-%
May 15, 2024	MORGAN STANLEY	added	18.51	-322	583	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-33.33	-68.00	38.00	-%
May 15, 2024	Kent Lake Capital LLC	added	322	457,733	810,628	0.35%
May 15, 2024	Steward Partners Investment Advisory, LLC	reduced	-89.3	-573	35.00	-%
May 15, 2024	Tower Research Capital LLC (TRC)	new	-	7,331	7,331	-%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	new	-	60.00	60.00	-%
May 15, 2024	Royal Bank of Canada	unchanged	-	-	-	-%
May 14, 2024	Front Row Advisors LLC	unchanged	-	-36.00	42.00	-%
May 14, 2024	NewEdge Advisors, LLC	new	-	272	272	-%

Are Funds Buying or Selling EKSO?

Are funds buying EKSO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own EKSO

No. of Funds

Unveiling Ekso Bionics Holdings Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 11, 2022	azimut investments s.a.	3.34%	423,000	SC 13G/A
Feb 12, 2021	azimut investments s.a.	086%	423,000	SC 13G
Nov 12, 2020	puissance cross-border opportunities ii llc	0.36%	29,828	SC 13D/A
Jun 18, 2020	armistice capital, llc	4.99%	398,692	SC 13G
Jun 16, 2020	intracoastal capital, llc	4.99%	387,369	SC 13G
Mar 05, 2020	puissance cross-border opportunities ii llc	13.3%	11,616,000	SC 13D/A
Dec 27, 2019	armistice capital, llc	4.99%	4,356,559	SC 13G

Recent SEC filings of Ekso Bionics Holdings Inc

View All Filings

Date Filed	Form Type	Document
Apr 29, 2024	8-K	Current Report
Apr 29, 2024	10-Q	Quarterly Report
Apr 26, 2024	DEFA14A	DEFA14A
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	ARS	ARS
Apr 04, 2024	4/A	Insider Trading
Apr 04, 2024	4	Insider Trading
Apr 04, 2024	4	Insider Trading
Mar 18, 2024	S-8	Employee Benefits Plan
Mar 18, 2024	11-K	Employee Benefit Details

Peers (Alternatives to Ekso Bionics Holdings Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.83%	-87.10%	-0.09	0.28	5.77%	8.23%

Ekso Bionics Holdings Inc News

Latest updates

Ekso Bionics Holdings Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-22.5%	3,756,000	4,847,000	4,607,000	4,703,000	4,122,000	3,619,000	3,329,000	3,329,000	2,567,000	4,076,000	3,049,000	2,211,000	1,910,000	1,126,500	2,897,000	2,264,000	1,468,000	3,720,000	3,319,000	3,262,000	3,616,000
Gross Profit	-17.6%	1,951,000	2,369,000	2,456,000	2,254,000	2,000,000	1,678,000	1,686,000	1,641,000	1,209,000	2,415,000	1,807,000	1,292,000	1,235,000	1,361,000	1,813,000	1,259,000	637,000	1,855,000	1,750,000	1,560,000	1,599,000
Operating Expenses	-10.5%	5,207,000	5,818,000	5,387,000	6,538,000	6,448,000	6,114,000	5,340,000	4,870,000	5,446,000	6,967,000	4,596,000	4,640,000	4,374,000	4,358,000	4,234,000	4,351,000	5,418,000	4,694,000	5,540,000	6,658,000	6,511,000
S&GA Expenses	-8.3%	1,818,000	1,983,000	2,052,000	2,349,000	2,088,000	1,945,000	1,742,000	1,841,000	1,629,000	2,040,000	1,685,000	1,787,000	1,793,000	1,780,000	1,740,000	1,712,000	2,520,000	2,732,000	2,818,000	3,039,000	2,809,000
R&D Expenses	-13.5%	1,136,000	1,313,500	1,159,000	1,398,000	1,154,000	945,500	887,000	873,000	921,000	619,000	618,000	709,000	603,000	712,000	599,000	452,000	711,000	564,000	1,149,000	1,499,000	1,384,000
EBITDA Margin	-	-	-	-	-	-	-	-	-0.66	-0.75	-0.81	-	-	-1.68	-1.76	-1.15	-1.10	-1.00	-0.84	-1.96	-2.07	-2.12
Interest Expenses	-13.0%	57,000	65,500	64,000	61,000	112,000	66,000	34,000	29,000	27,000	36,000	24,000	27,000	26,000	26,000	23,000	38,000	52,000	68,000	88,000	107,000	121,000
Income Taxes	-100.0%	-	12,000	1,000	-	-	-1,000	10,000	-	-	104,000	-	-	-	103,000	6,000	-3,000	3,000	301,000	-	8,000	-
EBT Margin	-	-	-	-	-	-	-	-	-0.74	-0.82	-0.87	-	-	-1.70	-1.78	-1.17	-1.13	-1.03	-0.87	-2.00	-2.12	-2.17
Net Income	-6.7%	-3,429,000	-3,214,000	-3,365,000	-4,230,000	-4,389,000	-3,178,000	-4,304,000	-2,978,000	-4,620,000	-2,863,000	-1,958,000	-1,273,000	-3,670,000	-3,976,000	2,452,000	-11,767,000	-2,534,000	-2,721,000	206,000	-3,066,000	-6,551,000
Net Income Margin	4.4%	-0.79	-0.83	-0.89	-1.02	-1.03	-1.17	-1.11	-0.95	-0.90	-0.87	-1.31	-0.79	-2.07	-	-	-	-	-	-	-	-
Free Cashflow	-113.5%	-3,474,000	-1,627,000	-3,370,000	-2,958,000	-4,256,000	-3,697,000	-2,731,000	-4,248,000	-4,206,000	-3,074,000	-2,475,000	-3,606,000	-2,000,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	0.1%	29.00	29.00	31.00	34.00	37.00	41.00	39.00	41.00	44.00	49.00	51.00	53.00	57.00	21.00	23.00	22.00	17.00	22.00	20.00	26.00	21.00
Current Assets	1.5%	21.00	20.00	22.00	25.00	28.00	31.00	37.00	39.00	43.00	48.00	49.00	51.00	55.00	18.00	22.00	20.00	14.00	19.00	17.00	22.00	17.00
Cash Equivalents	1.9%	9.00	9.00	10.00	13.00	16.00	21.00	29.00	32.00	36.00	40.00	43.00	46.00	50.00	13.00	15.00	13.00	9.00	11.00	8.00	13.00	9.00
Inventory	1.1%	5.00	5.00	5.00	6.00	6.00	5.00	4.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	3.00	4.00	3.00
Net PPE	-7.7%	2.00	2.00	2.00	2.00	2.00	3.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00
Goodwill	0%	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-8.6%	15.00	16.00	16.00	16.00	16.00	15.00	11.00	9.00	11.00	12.00	12.00	13.00	16.00	16.00	15.00	22.00	12.00	15.00	14.00	20.00	16.00
Current Liabilities	-9.9%	7.00	8.00	8.00	10.00	10.00	9.00	8.00	5.00	6.00	7.00	5.00	5.00	6.00	5.00	5.00	7.00	8.00	8.00	8.00	9.00	10.00
Shareholder's Equity	11.5%	14.00	13.00	15.00	18.00	21.00	25.00	29.00	32.00	33.00	37.00	39.00	40.00	41.00	4.00	8.00	-	5.00	7.00	6.00	5.00	5.00
Retained Earnings	-1.4%	-242	-239	-235	-232	-228	-223	-220	-216	-213	-208	-206	-204	-202	-199	-195	-197	-185	-183	-180	-180	-177
Additional Paid-In Capital	1.8%	256	252	250	250	249	249	248	247	247	246	245	245	244	204	204	198	191	190	187	186	182
Shares Outstanding	21.9%	18.00	15.00	14.00	14.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	12.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	19.00	-	-	-	19.00	-	-	-	64.00	-	-	-	52.00	-	-	-	68.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-118.8%	-3,466	-1,584	-3,353	-2,903	-4,214	-3,644	-2,590	-4,248	-4,206	-3,075	-2,475	-3,606	-2,000	-1,740	-1,270	-4,023	-1,722	-1,495	-4,569	-4,531	-5,177
Share Based Compensation	-21.5%	376	479	441	514	424	928	537	582	499	791	663	519	356	798	517	508	587	575	487	557	636
Cashflow From Investing	81.4%	-8.00	-43.00	-17.00	-55.00	-42.00	-5,034	-141	-	-	1.00	-	-	-	-	-	-	-	-	-	-53.00	-7.00
Cashflow From Financing	-	3,657	-	-	-	-	-	-	-	-	-	-	-	38,712	-	2,544	8,749	-589	4,269	-598	8,599	6,769

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

EKSO Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue	$ 3,756	$ 4,122
Cost of revenue	1,805	2,122
Gross profit	1,951	2,000
Operating expenses:
Sales and marketing	1,818	2,088
Research and development	1,136	1,154
General and administrative	2,253	3,206
Total operating expenses	5,207	6,448
Loss from operations	(3,256)	(4,448)
Other (expense) income, net:
Interest expense, net	(57)	(112)
Loss on modification of warrant	(109)	0
Gain (loss) on revaluation of warrant liabilities	342	(26)
Unrealized (loss) gain on foreign exchange	(349)	217
Other income (expense), net	0	(20)
Total other (expense) income, net	(173)	59
Net loss	(3,429)	(4,389)
Other comprehensive income (loss)	291	(194)
Comprehensive loss	$ (3,138)	$ (4,583)
Net loss per share applicable to common shareholders, basic and diluted (in dollars per share)	$ (0.2)	$ (0.33)
Weighted average number of shares outstanding, basic and diluted (in shares)	17,419	13,296

EKSO Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and restricted cash	$ 8,799	$ 8,638
Accounts receivable, net of allowances of $16 and $79, respectively	5,773	5,645
Inventories	5,106	5,050
Prepaid expenses and other current assets	838	875
Total current assets	20,516	20,208
Property and equipment, net	1,862	2,018
Right-of-use assets	893	977
Intangible assets, net	4,815	4,892
Goodwill	431	431
Other assets	440	392
Total assets	28,957	28,918
Current liabilities:
Accounts payable	1,876	1,847
Accrued liabilities	1,786	2,664
Deferred revenues, current	2,028	1,993
Note payable, current	1,250	1,250
Lease liabilities, current	372	363
Total current liabilities	7,312	8,117
Deferred revenues	2,119	2,169
Notes payable, net	4,594	4,832
Lease liabilities	626	723
Warrant liabilities	133	366
Other non-current liabilities	122	105
Total liabilities	14,906	16,312
Commitments and contingencies (Note 14)
Stockholders’ equity:
Convertible preferred stock, $0.001 par value; 10,000 shares authorized; none issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock, $0.001 par value; 141,429 shares authorized; 18,096 and 14,848 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	18	15
Additional paid-in capital	256,160	251,580
Accumulated other comprehensive income	447	156
Accumulated deficit	(242,574)	(239,145)
Total stockholders’ equity	14,051	12,606
Total liabilities and stockholders’ equity	$ 28,957	$ 28,918

About Ekso Bionics Holdings Inc

Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The company also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therap, an adjustable and lower-limb powered exoskeleton; and Ekso Indego Personal, a powered lower limb orthosis. It has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in San Rafael, California.

CEO	Mr. Scott G. Davis
WEBSITE	eksobionics.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	72

Ekso Bionics Holdings Inc Frequently Asked Questions

What is the ticker symbol for Ekso Bionics Holdings Inc? What does EKSO stand for in stocks?

EKSO is the stock ticker symbol of Ekso Bionics Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ekso Bionics Holdings Inc (EKSO)?

As of Fri May 17 2024, market cap of Ekso Bionics Holdings Inc is 24.72 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EKSO stock?

You can check EKSO's fair value in chart for subscribers.

What is the fair value of EKSO stock?

You can check EKSO's fair value in chart for subscribers. The fair value of Ekso Bionics Holdings Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ekso Bionics Holdings Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EKSO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ekso Bionics Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether EKSO is over valued or under valued. Whether Ekso Bionics Holdings Inc is cheap or expensive depends on the assumptions which impact Ekso Bionics Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EKSO.

What is Ekso Bionics Holdings Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, EKSO's PE ratio (Price to Earnings) is -1.74 and Price to Sales (PS) ratio is 1.38. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EKSO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Ekso Bionics Holdings Inc's stock?

In the past 10 years, Ekso Bionics Holdings Inc has provided -0.249 (multiply by 100 for percentage) rate of return.